UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A modified MethyLight assay predicts the clinical outcomes of anti‐epidermal growth factor receptor treatment in metastatic colorectal cancer

Cancer science, 2022-03, Vol.113 (3), p.1057-1068

2022

Volltextzugriff (PDF)

Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03)

Supportive care in cancer, 2020-08, Vol.28 (8), p.3649-3657

2020

Volltextzugriff (PDF)

Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers

Cancer chemotherapy and pharmacology, 2021-09, Vol.88 (3), p.393-402

2021

Volltextzugriff (PDF)

Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo

Cancer science, 2009-05, Vol.100 (5), p.956-960

2009

Volltextzugriff (PDF)

Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203)

The Tohoku Journal of Experimental Medicine, 2021, Vol.254(1), pp.49-55

2021

Volltextzugriff (PDF)

Curcumin analog GO‐Y030 is a novel inhibitor of IKKβ that suppresses NF‐κB signaling and induces apoptosis

Cancer science, 2011-05, Vol.102 (5), p.1045-1051

2011

Volltextzugriff (PDF)

Multiple cavitary lung lesions from colorectal cancer responding to chemotherapy

Respiratory medicine case reports, 2023-01, Vol.44, p.101865, Article 101865

2023

Volltextzugriff (PDF)

Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer

Molecular cancer therapeutics, 2006-10, Vol.5 (10), p.2563-2571

2006

Volltextzugriff (PDF)

Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis

PloS one, 2017-05, Vol.12 (5), p.e0176972-e0176972

2017

Volltextzugriff (PDF)

P4-2 Efficacy and eligibility predictors of trifluridine/tipiracil biweekly regimen in advanced colorectal cancer

Annals of oncology, 2021-07, Vol.32, p.S331-S331

2021

Volltextzugriff (PDF)

Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis

The Tohoku Journal of Experimental Medicine, 2018, Vol.245(2), pp.123-129

2018

Volltextzugriff (PDF)

Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study

The Tohoku Journal of Experimental Medicine, 2018, Vol.245(1), pp.21-28

2018

Volltextzugriff (PDF)

O11-3 Usefulness of the MEWS as an ultra-short-term prognosis predictor for patients with gastrointestinal cancer

Annals of oncology, 2022-07, Vol.33, p.S473

2022

Volltextzugriff (PDF)

Real‐world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6‐NTRK3 positive metastatic salivary secretory carcinoma: A case series

Head & neck, 2023-05, Vol.45 (5), p.E10-E15

2023

Volltextzugriff (PDF)

Syntheses of naturally occurring cytotoxic [7.7]paracyclophanes, (-)-cylindrocyclophane A and its enantiomer, and implications for biological activity

Organic & biomolecular chemistry, 2009-01, Vol.7 (18), p.3772-3781

2009

Volltextzugriff (PDF)

Synthesis of 86 species of 1,5-diaryl-3-oxo-1,4-pentadienes analogs of curcumin can yield a good lead in vivo

BMC pharmacology, 2011-05, Vol.11 (1), p.4-4, Article 4

2011

Volltextzugriff (PDF)

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2023-04, Vol.329 (15), p.1271

2023

Volltextzugriff (PDF)

Thyroid dysfunction (hypothyroidism and hyperthyroidism)

Nihon rinshō, 2015-02, Vol.73 Suppl 2, p.422

Ohori, Hisatsugu

2015

Volltextzugriff (PDF)

Safety Verification Trials of mFOLFIRI and Sequential IRIS + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients

Oncology, 2012, Vol.83 (2), p.101-107

2012

Volltextzugriff (PDF)

Genome-wide DNA methylation status to predict the efficacy of modified (m)-FOLFOXIRI plus cetuximab as initial treatment for RAS wild-type metastatic colorectal cancer: A biomarker study of the DEEPER trial (JACCRO CC-13AR)

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.152-152

2024

Volltextzugriff (PDF)

PS4-4 Early tumor shrinkage and depth of response with first-line panitumumab or bevacizumab and mFOLFOX treatment in PARADIGM

Annals of oncology, 2023-11, Vol.34, p.S1382-S1382

2023

Volltextzugriff (PDF)

Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS / BRAF WT: A biomarker study of the phase III PARADIGM trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3508-3508

2023

Volltextzugriff (PDF)

Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.11-11

2023

Volltextzugriff (PDF)

Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer: Survival analysis of the phase II randomized DEEPER trial by JACCRO

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.120-120

2023

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(53)
Berichte
(2)

Sprache

Englisch
(47)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Humans
(21)
Life Sciences & Biomedicine
(20)
Chemotherapy
(12)
Male
(12)
Oncology
(12)
Aged
(10)
Tumors
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Colorectal Cancer
(9)
Female
(9)
Adult
(8)
Cancer
(7)
Bevacizumab
(6)
Colorectal Neoplasms - Drug Therapy
(6)
Metastases
(6)
Metastasis
(6)
Middle Aged
(6)
Patients
(6)
Survival
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A modified MethyLight assay predicts the clinical outcomes of anti‐epidermal growth factor receptor treatment in metastatic colorectal cancer

Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03)

Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers

Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo

Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203)

Curcumin analog GO‐Y030 is a novel inhibitor of IKKβ that suppresses NF‐κB signaling and induces apoptosis

Multiple cavitary lung lesions from colorectal cancer responding to chemotherapy

Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer

Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis

P4-2 Efficacy and eligibility predictors of trifluridine/tipiracil biweekly regimen in advanced colorectal cancer

Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis

Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study

O11-3 Usefulness of the MEWS as an ultra-short-term prognosis predictor for patients with gastrointestinal cancer

Real‐world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6‐NTRK3 positive metastatic salivary secretory carcinoma: A case series

Syntheses of naturally occurring cytotoxic [7.7]paracyclophanes, (-)-cylindrocyclophane A and its enantiomer, and implications for biological activity

Synthesis of 86 species of 1,5-diaryl-3-oxo-1,4-pentadienes analogs of curcumin can yield a good lead in vivo

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial

Thyroid dysfunction (hypothyroidism and hyperthyroidism)

Safety Verification Trials of mFOLFIRI and Sequential IRIS + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients

Genome-wide DNA methylation status to predict the efficacy of modified (m)-FOLFOXIRI plus cetuximab as initial treatment for RAS wild-type metastatic colorectal cancer: A biomarker study of the DEEPER trial (JACCRO CC-13AR)

PS4-4 Early tumor shrinkage and depth of response with first-line panitumumab or bevacizumab and mFOLFOX treatment in PARADIGM

Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS / BRAF WT: A biomarker study of the phase III PARADIGM trial

Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer

Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial

Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer: Survival analysis of the phase II randomized DEEPER trial by JACCRO

Suchergebnisse filtern